The drug company accused four compound pharmacies of violating state laws becaus...
The current primary care physician workforce cannot sustain value-based payment ...
"It's very clear in our data that reinfection contributes additional risk of lon...
A new wave of AI-powered tools promises to boost dentists’ ability to spot decay...
The Apellis eye drug rebound accelerates. This time, it's a competitor falling b...
"The idea here is you can still get a patent but it wouldn’t be implemented as a...
An FDA panel, assessing the artificial womb technology, grappled with the limits...
Congress wants PBM reforms to help lower the cost of medicines — but don’t think...
Data from one of Pear Therapeutics' key deals is driving conversations about how...
MK-0616 is a peptide commercialized by Merck, with a leading Phase III program i...
The company will suspend the development of three assets, considering strategic ...
We interviewed Datwyler’s Gabrielle Gehron to understand the best sourcing strat...
European Commission has approved the oral combination drug for treating newly di...
The company plans to refile the IND after assessing the feasibility of US FDA-su...
Pelican Technology has combined business with Primordial Genetics under a deal t...
Orexo has submitted a new drug application (NDA) to the US FDA for its high-dose...
